Scarica l'app Stockscreener
85.69
7.25%
5.79
Pre-mercato:
85.67
-0.02
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$79.90
Aprire:
$79.9
Volume 24 ore:
1.12M
Relative Volume:
0.62
Capitalizzazione di mercato:
$8.01B
Reddito:
$688.00K
Utile/perdita netta:
$-168.74M
Rapporto P/E:
-36.34
EPS:
-2.3577
Flusso di cassa netto:
$-185.87M
1 W Prestazione:
-7.58%
1M Prestazione:
-5.42%
6M Prestazione:
+67.07%
1 anno Prestazione:
+347.70%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$77.05
$92.08
Portata 52W:
$17.65
$110.17
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
85.69 | 8.01B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
510.08 | 129.29B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
225.00 | 89.83B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
746.54 | 76.86B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
825.03 | 51.88B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.67B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-01 | Iniziato | JP Morgan | Overweight |
| 2026-07-28 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2026-04-14 | Iniziato | Raymond James | Strong Buy |
| 2025-12-18 | Iniziato | Mizuho | Outperform |
| 2025-12-17 | Iniziato | Citigroup | Buy |
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It? - Yahoo Finance
Spyre Therapeutics at Wells Fargo conference: betting on combination biologics - Investing.com Canada
Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10 - marketscreener.com
Spyre Therapeutics at Citi summit: bets on autoimmune combinations By Investing.com - Investing.com Canada
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - The Globe and Mail
Spyre Therapeutics Inc at Citi Biopharma Back to School Summit Transcript - GuruFocus
Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study - Yahoo Finance
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com South Africa
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com Nigeria
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com Canada
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com India
Guggenheim Reveals Top Biotech Stock After Positive Clinical Trial Data By Investing.com - Investing.com UK
SYRE Reiterated by Wedbush -- Maintained Price Target at $123 - GuruFocus
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com India
Baird reiterates Spyre stock Outperform rating on positive trial data By Investing.com - Investing.com Canada
SYRE Reiterated by BTIG -- Price Target Maintained at $121 - GuruFocus
Spyre Therapeutics (SYRE) Reports Positive Phase 2 SKYLINE Trial Results Amid High Valuation Concerns - GuruFocus
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com Canada
Spyre reports positive ulcerative colitis trial data for SPY003 By Investing.com - Investing.com India
Spyre reports positive ulcerative colitis trial data for SPY003 - Investing.com
An experimental ulcerative colitis treatment cut a disease score by 10 points - Stock Titan
Spyre posts positive Phase 2 SKYLINE Part A: SPY003 cuts RHI 10.0 pts; Part B enrolling, topline in 2027 - TradingView
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations - Yahoo Finance
Spyre Therapeutics Announces Grants of Inducement Awards - manilatimes.net
Spyre Therapeutics Insider Sold Shares Worth $1,309,410, According to a Recent SEC Filing - marketscreener.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares By Investing.com - Investing.com South Africa
Spyre Therapeutics (SYRE) CEO Cameron Turtle Sells 15,000 Shares - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Nigeria
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares - investing.com
Spyre Therapeutics officer Heidy King-Jones sells $2.48m in shares - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares - Investing.com
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com India
Spyre Therapeutics CFO Scott Burrows sells $2.28m in shares By Investing.com - Investing.com Canada
Spyre Therapeutics CEO Cameron Turtle sells $1.3m in shares By Investing.com - Investing.com UK
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $36,000.00 in Stock - MarketBeat
Spyre Therapeutics (SYRE) CFO sells over 25K shares in planned trades - Stock Titan
Spyre Therapeutics (SYRE) officer sells stock from option exercise at prices up to $90 - Stock Titan
Spyre Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Three September conferences will include Spyre Therapeutics. Webcasts will be available. - Stock Titan
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Spyre Therapeutics (SYRE) CEO sells shares in preset plan - Stock Titan
Multimillion-dollar stock sale planned by Spyre Therapeutics (SYRE) officer—see how many shares are on the block - Stock Titan
Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked - finance.yahoo.com
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles - Sahm
Spyre reveals mid-stage miss for TL1A antibody in rheumatoid arthritis - The Pharma Letter
Spyre Therapeutics: Catalyst-Rich Period But Easiest Money May Have Been Made (Downgrade) - Seeking Alpha
SYRE Stock Sinks After Mixed SKYWAY Study Data in Rheumatoid Arthritis - TradingView
Stifel reiterates Spyre stock Buy rating after RA study results By Investing.com - Investing.com Nigeria
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spyre Therapeutics Inc Azioni (SYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Burrows Scott L | Chief Financial Officer |
Oct 01 '26 |
Sale |
91.83 |
7,500 |
688,756 |
79,762 |
| CAMERON TURTLE | Director |
Oct 01 '26 |
Proposed Sale |
89.03 |
45,000 |
4,006,350 |
0 |
| King-Jones Heidy | See Remarks |
Oct 01 '26 |
Sale |
91.03 |
28,933 |
2,633,902 |
2,845 |
| HEIDY KING-JONES | Officer |
Oct 01 '26 |
Proposed Sale |
89.03 |
29,335 |
2,611,695 |
0 |
| Turtle Cameron | Chief Executive Officer |
Oct 01 '26 |
Sale |
92.01 |
15,000 |
1,380,105 |
537,540 |
| Burrows Scott L | Chief Financial Officer |
Oct 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
87,262 |
| Burrows Scott L | Chief Financial Officer |
Sep 30 '26 |
Option Exercise |
14.50 |
17,500 |
253,750 |
97,262 |
| SCOTT BURROWS | Officer |
Sep 30 '26 |
Proposed Sale |
89.89 |
17,500 |
1,573,157 |
0 |
| Burrows Scott L | Chief Financial Officer |
Sep 30 '26 |
Sale |
89.89 |
17,500 |
1,573,075 |
79,762 |
| King-Jones Heidy | See Remarks |
Sep 02 '26 |
Sale |
90.00 |
400 |
36,000 |
2,845 |
1.01%
8.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):